russ2000_2_0017|AGE|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
russ2000_2_0017|AGE|1|AgeX Therapeutics Inc Total Current Assets (Quarterly) (USD)|AgeX Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|AgeX Therapeutics Inc Inventories (Quarterly) (USD)|AgeX Therapeutics Inc Net PP&E (Quarterly) (USD)|AgeX Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|AgeX Therapeutics Inc Total Liabilities (Quarterly) (USD)|AgeX Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|AgeX Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|AgeX Therapeutics Inc Total Deposits (Quarterly) (USD)|AgeX Therapeutics Inc Book Value (Quarterly) (USD)|AgeX Therapeutics Inc Retained Earnings (Quarterly) (USD)|AgeX Therapeutics Inc Treasury Stock (Quarterly) (USD)|AgeX Therapeutics Inc EV to Revenues|AgeX Therapeutics Inc EV to Earnings|AgeX Therapeutics Inc EV to Free Cash Flow|AgeX Therapeutics Inc EV to Assets (Quarterly)|AgeX Therapeutics Inc PS Ratio|AgeX Therapeutics Inc PE Ratio|AgeX Therapeutics Inc Price to Book Value|AgeX Therapeutics Inc PEG Ratio|AgeX Therapeutics Inc Debt to Equity Ratio|AgeX Therapeutics Inc Dividend Yield|AgeX Therapeutics Inc Shareholder Yield (TTM)|AgeX Therapeutics Inc Percent of Shares Outstanding Short|AgeX Therapeutics Inc Total Receivables (Quarterly) (USD)|AgeX Therapeutics Inc Total Payables (Quarterly) (USD)|AgeX Therapeutics Inc Total Capital Stock (Quarterly) (USD)|AgeX Therapeutics Inc Return on Invested Capital|AgeX Therapeutics Inc Quality Ratio Score|AgeX Therapeutics Inc Momentum Score|AgeX Therapeutics Inc Beta (1Y)|AgeX Therapeutics Inc Sustainable Growth Rate (TTM)|AgeX Therapeutics Inc Institutional Investor Ownership Percentage|AgeX Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|AgeX Therapeutics Inc Total Employees (Annual)|AgeX Therapeutics Inc EPS Diluted (Quarterly) (USD)|AgeX Therapeutics Inc SG&A Expense (Quarterly) (USD)|AgeX Therapeutics Inc Shares Outstanding|AgeX Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|AgeX Therapeutics Inc Ordinary Shares Number (Quarterly)|AgeX Therapeutics Inc Payout Ratio|AgeX Therapeutics Inc Quick Ratio (Quarterly)|AgeX Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|AgeX Therapeutics Inc Stock Buybacks (Quarterly) (USD)|AgeX Therapeutics Inc Effective Tax Rate (TTM)|AgeX Therapeutics Inc Return on Equity|AgeX Therapeutics Inc Net Income (TTM) (USD)|AgeX Therapeutics Inc Revenue (TTM) (USD)|AgeX Therapeutics Inc Dividend Per Share (Quarterly) (USD)|AgeX Therapeutics Inc Revenue (Quarterly) (USD)|AgeX Therapeutics Inc Gross Profit (Quarterly) (USD)|AgeX Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|AgeX Therapeutics Inc Net Income (Quarterly) (USD)|AgeX Therapeutics Inc Net Interest Income (Quarterly) (USD)|AgeX Therapeutics Inc Price (USD)|AgeX Therapeutics Inc Total Return Price (USD)|AgeX Therapeutics Inc Enterprise Value (USD)|AgeX Therapeutics Inc 30-Day Average Daily Volume|AgeX Therapeutics Inc 1 Year Price Returns (Daily)|AgeX Therapeutics Inc Short Interest|AgeX Therapeutics Inc PE Ratio (Forward)|AgeX Therapeutics Inc PE Ratio (Forward 1y)|AgeX Therapeutics Inc PS Ratio (Forward)|AgeX Therapeutics Inc PS Ratio (Forward 1y)|AgeX Therapeutics Inc Quarterly EPS Estimates (USD)|AgeX Therapeutics Inc Quarterly Revenue Estimates (USD)|AgeX Therapeutics Inc Quarterly EPS Surprise|AgeX Therapeutics Inc Quarterly Revenue Surprise|AgeX Therapeutics Inc Quarterly Actual EPS (USD)|AgeX Therapeutics Inc Quarterly Actual Revenue (USD)|AgeX Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|AgeX Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|AgeX Therapeutics Inc Price Target (USD)|AgeX Therapeutics Inc Consensus Recommendation|AgeX Therapeutics Inc Price Target Num Estimates|AgeX Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|AgeX Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|AgeX Therapeutics Inc Research and Development Expense (Quarterly) (USD)|AgeX Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|AgeX Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|AgeX Therapeutics Inc Land and Improvements (Quarterly) (USD)|AgeX Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|AgeX Therapeutics Inc Other Properties (Quarterly) (USD)|AgeX Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
russ2000_2_0017|AGE|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
russ2000_2_0017|AGE|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|daily|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
russ2000_2_0017|AGE|5|91.2727272727|91.2727272727||91.2222222222|91.2727272727|91.2727272727|91.2727272727|91.2727272727||91.2727272727|91.2727272727||6.93939393939|91.2727272727|6.98170731707|91.2727272727|6.98170731707||1.44444444444|1.45967741935|91.2727272727|1.4512946979|91.2727272727|15.2368421053|91.2727272727|91.2727272727|91.2727272727|91.4444444444|91.4444444444|31.75|30.5|91.5|30.5|91.3571428571|365.5|91.3571428571|91.3571428571|33.65625||91.2727272727|91.2727272727|91.2727272727|91.3571428571|91.3846153846|91.25|91.5|91.2727272727|91.2727272727||91.3571428571|91.3571428571|91.3571428571|91.3571428571|91.3571428571|6.96449704142|6.96449704142|6.98170731707|6.98148148148|1.45|15.2368421053||||||||||||||||||91.3571428571|91.3571428571|91.4|||91.6|91.2222222222||
russ2000_2_0017|AGE|6|11|11||9|11|11|11|11||11|11||165|11|164|11|164||315|124|11|811|11|76|11|11|11|9|9|24|26|4|14|14|2|14|14|32||11|11|11|14|13|4|4|11|11||14|14|14|14|14|169|169|164|162|560|76||||||||||||||||||14|14|5|||5|9||
russ2000_2_0017|AGE|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
russ2000_2_0017|AGE|201803||||||||||||||||||||||||||||||||||35.8||-0.0066|1.29||||||-0.0066|||||||0.239|0.13|-0.321|-0.235|0.018||||||||||||||||||||||||2.391|0.122|||||||
russ2000_2_0017|AGE|201806||||||||||||||||||||||||||||||||||35.8||-0.0539|1.135||||||-0.0539|-5||||||0.464|0.385|-1.951|-1.93|0.027||||||||||||||||||||||||1.384|0.117|||||||
russ2000_2_0017|AGE|201809||||||||||||||||||||||||1.3241||||||||||35.8||-0.0601|1.254|35.8|||||-0.0601|||||||0.38|0.384|-2.185|-2.151|0.039|2.71|2.71||||474012||||||||||||||||||1.332|0.146|||||||
russ2000_2_0017|AGE|201812|7.853|6.707||0.09|2.709|2.44|2.44|||7.447|-74.054||72.4991|-13.4909|-10.2355|9.4845|76.6937||14.3859|||||3.1326|0.131|1.244|0.004|||||||35.83|12|-0.09|1.968|35.83||35.83||2.8025|-0.09||||-7.502|1.396||0.313|0.133|-3.274|-3.186|0.032|2.99|2.99|101.2087|125915.5333||1122420||||||||||||||||||1.523|0.15|||||0.245|3.88|4.51
russ2000_2_0017|AGE|201903|9.648|8.586||0.084|2.57|2.294|2.294|||9.321|-77.187||108.4315|-13.8963|-15.3085|11.7297|107.2173||18.4093||||-3.2808|2.6443|0.206|1.158|0.004|||||||36.143||-0.09|2.109|37.63||37.63||3.8326|-0.09||-0.6921||-10.4|1.545||0.388|0.325|-3.138|-3.133|0.012|4.18|4.18|151.3704|61969.3333||995051||||||||||||||||||1.338|0.149||||||4.56|2.65
russ2000_2_0017|AGE|201906|6.68|5.813||0.951|2.43|2.85|2.629|0.221||6.747|-80.276||89.888|-11.5018|-13.4208|12.9618|90.6043||16.3415|||||2.5102|0.208|1.242|0.004|-135.114|3|||-147.4676||37.63||-0.08|2.119|37.63||37.63||2.2902|-0.08||-0.6469|-147.4676|-11.559|1.461||0.38|0.327|-3.152|-3.089|0.033|3.9|3.9|130.2221|97698.6667||944584||||||||||||||||||1.65|0.251||||0.726|0.335|2.76|2.55
russ2000_2_0017|AGE|201909|4.69|3.768||1.01|2.29|3.24|2.907|0.333||4.339|-83.497||55.7424|-5.6077|-7.1464|8.6544|57.2257||17.0067||0.044||-0.0518|2.0586|0.234|1.56|0.004|-164.0183|3||4.2548|-181.3599||37.64||-0.09|2.194|37.649||37.649||1.3767|-0.09||-1.0167|-181.3599|-12.629|1.492||0.411|0.362|-3.223|-3.221|0.008|2.3|2.3|74.2864|77743.3667|-47.6015|775033||||||||||||||||||1.447|0.257||||0.726|0.353|1.48|1.61
russ2000_2_0017|AGE|201912|4.054|2.352||1.126|2.151|4.825|3.297|1.528||2.218|-86.208||39.4075|-5.6028|-6.1667|9.1503|39.2511||30.8932|-0.0871|0.6889||-0.446|2.3155|0.363|1.383|0.004|-173.9068|4|1|4.9074|-202.0817||37.655|17|-0.08|1.717|37.649||37.649||0.8235|-0.08||-1.2095|-202.0817|-12.154|1.728||0.549|0.47|-2.723|-2.711|-0.024|1.82|1.82|62.5363|95563.9667|-39.1304|871750||||||||||||||||||1.469|0.294||||0.726|0.954|1.71|1.21
russ2000_2_0017|AGE|202003|2.072|0.468||0.898|2.011|5.467|5.467|||-0.739|-89.395||20.5544|-3.0049|-2.7846|7.2041|24.4989||15.7892|-0.2301|-2.3911||-1.0091|3.469|0.366|2.067|0.004|-217.1856|3|1|2.1385|-278.8998||37.651||-0.08|1.875|37.6564||37.6564||0.1526|-0.08|||-278.8998|-12.208|1.429||0.089|0.088|-3.033|-3.187|-0.03|0.93|0.93|30.0767|98820.0333|-77.037|1306311||||||||||||||||||1.221|0.26||||0.726|0.864|0.83|0.7856
russ2000_2_0017|AGE|202006|2.104|1.033||0.681|1.872|6.879|5.147|1.732||-2.444|-92.084||23.9684|-3.2966|-3.6229|8.1831|32.5813|||-0.2474|-1.6313||-2.2367|3.8719|0.235|1.56|0.004|-296.0437|4|2|0.9203|-583.3416||37.657||-0.07|1.475|37.658||37.658||0.2464|-0.06|||-583.3416|-11.808|1.094||0.045|0.042|-2.432|-2.689|-0.065|0.9467|0.9467|37.1278|703761.6333|-74.2044|1458094||||||||||||||||||0.935|0.261|0.065|||0.726|0.876|1.23|0.8959
russ2000_2_0017|AGE|202009|1.929|1.107||0.442|1.732|7.949|4.854|3.095||-3.651|-94.627||46.1969|-3.1213|-3.6268|8.2655|27.3605||||-1.4829||-3.5469|3.6624|0.241|1.604|0.004|-391.791|3|1|0.8961||66.8599|37.679||-0.07|1.796|37.689||37.689||0.2777|-0.07||||-11.13|0.752||0.069|0.052|-2.524|-2.543|-0.127|0.795|0.795|34.9293|183423.7|-58.6735|1380330||||||||||||||||||0.653|0.263|0.127|||0.726|0.846|1.88|1.76
russ2000_2_0017|AGE|202012|2.283|0.527|||1.592|9.321|5.357|3.964||-5.116|-97.073||88.2963|-5.7781|-7.4413|15.9947|82.6327||||-1.2306||-2.1313|1.1417|0.326|1.499|0.004|-544.8847|8|7|0.2012||66.4066|37.69|11|-0.07|2.257|37.691||37.691||0.1592|-0.08||||-10.865|1.868||1.665|1.528|-3.137|-2.446|-0.277|1.5712|1.5712|66.3988|242365.2667|-16.4835|430302||||||||||||||||||2.169|0.898|||||0.381|1.85|2.16
russ2000_2_0017|AGE|202103|2.142|0.809|||0.968|9.263|3.929|5.334||-6.062|-99.161||36.0403|-6.9587|-8.5904|21.506|32.8698||||-1.2131||-2.7031|1.6101|0.048|1.057|0.004|-690.0791|7|7|-2.3311||66.6667|37.729||-0.06|2.022|37.9351||37.9351||0.2181|-0.0528|-0.496|||-9.766|1.835||0.056|0.053|-1.993|-2.088|-0.243|1.63|1.63|67.3232|346229.6|74.1935|610784||||||||||||||||||0.324|0.033|||||0.381|1.42|1.2
russ2000_2_0017|AGE|202106|1.556|0.615|||0.935|10.835|5.271|5.564||-8.252|-101.635||38.2752|-7.0432|-8.3783|26.4736|34.5052||||-1.1057||-3.3458|1.7471|0.011|1.201|0.004|-733.1133|9|3|-2.8888||65.4267|37.936||-0.07|1.748|37.937||37.937||0.1188|-0.07||||-9.551|1.827||0.037|0.024|-2.475|-2.474|-0.274|1.68|1.68|70.235|97665.7|63.7266|662804||||||||||||||||||0.481|0.033|0.274|||||1.325|1.03
russ2000_2_0017|AGE|202109|1.475|0.731|||0.902|12.405|6.598|5.807||-9.936|-103.59||24.3608|-5.1653|-5.682|19.0757|19.6336||||-1.148||-5.552|1.1865|0.024|0.794|0.004|-737.3314|8|4|-2.6473||63.3623|37.938||-0.05|1.421|37.939||37.939||0.1144|-0.05||||-8.963|1.782||0.024|0.022|-1.955|-1.955|-0.285|0.95|0.95|44.5072|66498.7|16.0494|450157||||||||||||||||||0.275|0.032|0.285|||||0.88|0.6999
russ2000_2_0017|AGE|202112|||||||||||||17.8942||-4.0735||12.0325|||||||1.0653||||||1|0.232||63.3653||||||||||||||||||||||0.5669|0.5669|31.8875|114092|-28.2895|404168|||||||||||||||||||||||||0.77|0.704